Form 144 Vaxcyte, Inc. Filed by: Eydelman Mikhail
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/3/2026
- Wall St set for higher open on Mideast deal hopes; healthcare in focus
- Fed's Williams says rate hikes possible if inflation persists
- Citi says buy these 3 chip stocks on pullback
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Deutsche Bank raises S&P 500 earnings estimates on the back of the solid Q2 beats
- Morgan Stanley Downgrades Circle Internet Group (CRCL) to Underweight
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Citi says buy these 3 chip stocks on pullback
- Myanmar's detained former leader Aung San Suu Kyi meets Red Cross official
- Tyson Foods (TSN) Misses Q3 EPS by 6c, Misses on Revenue; Offers Guidance
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Leerink Partners Reiterates Outperform Rating on Vaxcyte (PCVX)
November 6, 2024 5:59 AM ESTLeerink Partners analyst David Risinger reiterated an Outperform rating and $135.00 price target on Vaxcyte (NASDAQ: PCVX).
The analyst comments "Bottom Line: PCVX reported OpEx of $140M which was +2% or +$3M vs. our est. of $137M. The companys pipeline remains on track; the next readout to watch is VAX-24 Ph2 infant data at the end of 1Q25. We remain bullish on PCVX following competitive PCV pipeline commentary from PFE (MP) and GSK (Not Rated). PFE disclosed on its on... More
